We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Bioquell | BQE | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 597.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 597.00 | 597.00 |
| Top Posts |
|---|
Posted at 07/1/2019 09:38 by bbluesky Good morning bountyhunter. One to look at imv is OMG, which rather like BQE back a while is debt free, just issued a special divi and coming out of a big investment cycle with world leading products. |
Posted at 30/11/2018 07:34 by modform Very pleased with the offer in the current market , well done to BQE management |
Posted at 30/11/2018 07:17 by mirabeau Well done. BQE holders have their Friday feeling |
Posted at 17/9/2018 15:03 by countless It's interesting to see that they have all moved in tandem recently. A share of future increased profits is well rewarded I expect in the hope that expectations are met, or exceeded going forward. I am sure BQE will exceed hisotical expectations but feel the share price has got ahead of its self a bit. The recent tip, and indeed the recent confirmation of that tip has, I think, pushed this too far and the TMF article airs on the side of caution. As you say you never know but I have a feeling that come end of year results at current levels there may be a correction. Now that's not to say this is not a good company - wished I had seen it early 2018 if not before! |
Posted at 16/9/2018 08:31 by countless I think BQE will beat expectatations too, however those expectations wereset months ago. I think the article was drawing attention to the need to be cautious as the share price has increased 60% since last reviewed by TMF site. In these situations the expected profit must now show a significant increase to warrent the current share price and therefore the TMF team state they frequently dissapoint as the increase does not match what has happened in the market.I would have thought a period of consolidtion is due now. I will get a mouse as this tracker thing is driving me made and I keep ending up on porn sites! |
Posted at 16/9/2018 00:09 by bountyhunter Thanks countless.Re banking some profits, I have already done that a while back but ended up wishing I hadn't! In my experience a company only says it expects to beat expectations when pretty sure of that so BQE almost certainly will do imo. Re laptops I use a cordless mouse as I can't stand those tracker pads! |
Posted at 15/9/2018 08:30 by countless The Motley Fool had an article on BQE yesterday folks. You should be able to find it via Google but in short it states 'having positioned itself for more predictable revenues and higher quality earnings, it now expects to exceed analyst predictions on full-year profit. The only downside to this is that the shares look even more expensive than before (tipped at 342p with a gain of 60%). At 45 times forecast earnings before today, investors will need to be very confident that BQE will keep its word. While I would not necessarily dispose of the stock just yet, it does pay to remember that high expectations frequently result in eventual disappointment'.If I was a holder and noting that momentum is falling I would bank some profits or at the very least protect them. Have to say I like the TMF website for info. Always balanced. BH i have a few interesting links for your new BB will post when not on laptop (not sure how to cut and paste without a mouse!) |
Posted at 03/9/2018 10:23 by countless Thank you bountyhunter. I just cannot see what will add significant turnover to justify current valuation. IC increased EPS to 12.5p so something needs to radically change -hence my thoughts of a new customer like the NHS when I first came across BQE. No doubt it's a well run company with no debt and medium term I can see a take up in its more specialised products but I think the share price has run away with itself. Saying that I will not try another short -learnt my lesson on that one.Off to find your new thread now. |
Posted at 03/9/2018 08:57 by bountyhunter A quick look at the results shows that "most of its revenues are generated from overseas customers" and "Bioquell's products and services are sold by wholly-owned Bioquell organisations in the UK, USA, France, Germany, Ireland, Singapore, China and through a network of international distributors" so BQE is not too dependent on UK NHS or private hospitals fortunately. Also it's encouraging that "with respect to profitability, the Board believes that the Company will exceed current market expectations for profit for the full year" so that may be driving the share price growth right now. I'll need to look into the details further but no time right now unfortunately!To find my FTSE thread just type FTSE into the EPIC code box at the top right of the page and you should find it (since no one is likely to check UKX). |
Posted at 02/9/2018 22:38 by countless I have sent you a PM bountyhunter because I was not sure if Money Week would be happy with me summarising their article to the whole world!Interesting article from Investors Chronicle - strange how share tipsters regurgitate stuff. I noticed Frontier Tech Investor increased their up to purchase price to £5.50 last week because of the momentum. My view is that a market cap of £128m cannot be supported with an expected profit of £3.5m - that's a whopping 36.5x especially because I think BQE will struggle to significantly increase their turnover. Their HPV product will not take off in the NHS even though it may be the gold standard. What they have sold to the NHS to date is pitiful - mainly because the NHS is bust.Why buy an expensive machine that pumps out bleach when good old elbow grease will do. Their other products are very specialised to the extent I do not think it can significantly increase turnover in the short/medium term. Five years away when cancer research is at a different stage then perhaps unless the competition moves in. The share price has raced too far ahead of itself. Best of luck to all though. I was wrong with my small short but think my logic here is sound. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
